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ABSTRACT
Long non-coding RNAs (lncRNAs) have been recently shown to play an important
role in gene regulation and normal cellular functions, and disease processes. However,
despite the overwhelming number of lncRNAs identified to date, little is known about
their role in cancer for vast majority of them. The present study aims to determine
whether lncRNAs can serve as prognostic markers in human breast cancer. We
interrogated the breast invasive carcinoma dataset of the Cancer Genome Atlas (TCGA)
at the cBioPortal consisting of ~ 1,000 cases. Among 2,730 lncRNAs analyzed, 577
lncRNAs had alterations ranging from 1% to 32% frequency, which include mutations,
alterations of copy number and RNA expression. We found that deregulation of 11
lncRNAs, primarily due to copy number alteration, is associated with poor overall
survival. At RNA expression level, upregulation of 4 lncRNAs (LINC00657, LINC00346,
LINC00654 and HCG11) was associated with poor overall survival. A third signature
consists of 9 lncRNAs (LINC00705, LINC00310, LINC00704, LINC00574, FAM74A3,
UMODL1-AS1, ARRDC1-AS1, HAR1A, and LINC00323) and their upregulation can
predict recurrence. Finally, we selected LINC00657 to determine their role in breast
cancer, and found that LINC00657 knockout significantly suppresses tumor cell
growth and proliferation, suggesting that it plays an oncogenic role. Together, these
results highlight the clinical significance of lncRNAs, and thus, these lncRNAs may
serve as prognostic markers for breast cancer.

including microRNAs and long non-coding RNAs
(lncRNAs) [1]. MicroRNAs have been shown to play
an important role in cancer initiation, progression and
metastasis, and they may serve as potential biomarkers for
cancer diagnosis and prognosis [2, 3]. Compared to well-

INTRODUCTION
The human genome is actively transcribed. Of
interest, protein-coding genes only account for ~2%
whereas the rest of transcripts are non-coding RNAs
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studied microRNAs, lncRNAs are poorly characterized.
To date, an overwhelming number of lncRNAs have been
identified [4, 5]. Based on genomic organization and
relationship to protein-coding genes, lncRNAs can be
classified into five groups [6]: 1) sense; 2); antisense; 3)
bidirectional; 4) intronic and 5) intergenic. Since lncRNA
research is still at an early stage, the function for the vast
majority of lncRNAs remains to be determined yet. In
particular, little is known whether lncRNAs can serve as
biomarkers for cancer diagnosis and prognosis.
Breast cancer is the second most common cancer in
women in the U.S. based on the latest information from
American Cancer Society (www.cancer.org). In 2015
about 231,840 new cases of invasive breast cancer will
be diagnosed in women and about 40,290 women will
die from breast cancer. Breast cancer is a heterogeneous
disease with a large number of genetic alterations. For
example, six subtypes have been identified based on gene
expression profile and the phenotype. They are luminal A,
luminal B, tumor enriched with human epidermal growth
factor receptor 2 (HER-2), basal-like, normal-like and
claudin-low subtype [7–10]. For example, luminal A is the
most common subtype characterized by the expression of
estrogen receptor (ER), progesterone receptor (PR), Bcl2 and absence of HER-2. It accounts for 50-60% of the
total breast cancer cases [8, 9]. The luminal B subtype is
characterized by the expression of ER, PR and absence of
HER-2. They can be differentiated from luminal A subtype
on the basis of high Ki-67 staining which indicates higher
proliferation rate [11]. The treatment for different subtypes
of breast cancer is often different. However, the molecular
pathogenesis of breast cancer remains poorly defined
due to its heterogeneity. Although expression of group of
specific microRNAs can be associated with cancer subtype
[12], it is not clear about the role of lncRNAs in this aspect,
and their clinical implication remains to be determined yet.
In the present study, we interrogated the breast
invasive carcinoma dataset of the Cancer Genome Atlas
(TCGA) at cBioPortal, and identified three lncRNA
signatures that can predict overall survival (OS) or
recurrence. Furthermore, we characterized one lncRNA
from the signatures, LINC00657, by knockout and cell
culture models and demonstrated that LINC00657 plays
an oncogenic role in breast cancer.

The cBioPortal recognized 2,553 of them as valid names
(Table S2). Although the vast majority of them had no
alterations, there were still quite a few lncRNAs with
various genetic alterations. For example, 577 lncRNAs
had alterations with alteration frequency ranging from 1%
to 32% (Table S2). Forty five lncRNAs had alterations
in 10% cases or above (Table S2); 10 of them (PVT1,
CCAT1, LINC00536, PCAT1, PCAT2, LINC00861,
CCDC26, LINC00977, BAALC-AS2 and LINC00535)
accounted for a total of 40% cases (Figure 1A). These
lncRNAs were all on chromosome 8q (Figure S1A)
and heavily overlapped, primarily due to copy number
alteration (CNA). Among them, PVT1 had the highest
frequency (32%) and the lowest was LINC00535 with
16% frequency. Of note, not all amplifications led to
upregulation; instead only 2 of them, PVT1 and BAALCAS2, had upregulation (Figure S1B). No downregulation
or mutations (missense or truncating mutation), were
found. Importantly, each of these lncRNAs except
for PVT1 revealed significant associations with OS
(Table S2). When all 10 lncRNAs were combined, their
alterations were also significantly associated with OS
(Logrank test p = 0.0365) (Figure 1B).
Since this primary search included all three
parameters (mutation, CNA and RNA expression) and most
of alterations were due to amplification and upregulation
(Figure S1B), we determined whether a single feature is
able to predict patient outcomes. This search identified
27% frequency for CNA alone and they were associated
with OS and logrank test p value was 0.00845 (Figure 1C)
among 960 samples. However, when expression was used
as a sole criterion, none of these 10 lncRNAs was able to
predict outcomes with a significant p value (not shown). Of
interest, all of them were located on chromosome 8q (from
8q22 to 8q24) (Table S3).
In this regard, chromosome 8q24 has been
identified in a large scale study as the most frequently
amplified region linked to different cancers [14, 15]. The
well-known oncogene Myc is at chromosome 8q24.21.
To determine whether these lncRNAs are closely
associated with Myc, we chose 2~3 genes from each
chromosome band from 8q21.13 to 8q24.3 to search the
alternations of putative copy number. The farer from
Myc, the smaller the changes of copy number become
(Figure S2A & B), suggesting that 8q24.21 is the center
of CNA. Although 8q24 is believed to be a susceptible
region, our analysis suggested that CNA for these
lncRNAs may involve an entire region from 8q11.1 to
8q24.3, and it is associated with OS.

RESULTS
Genetic alterations of lncRNAs and patient
overall survival (OS)

Alterations of lncRNAs in RNA expression
and OS

Long non-coding RNAs (lncRNAs) are a very large
mixed group of non-coding RNAs that are arbitrarily
defined as larger than 200 bp in length [13]. Hence, we
performed a primary search starting with 2730 lncRNAs
primarily consisting of long intervening non-coding
RNAs (lincRNAs) and anti-sense lncRNAs (Table S1).
www.impactjournals.com/oncotarget
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alterations, and these data are obtained largely through
genomic DNA copy number arrays [16]. Given that deep
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sequencing becomes widely used and it provides more
valuable information, we tried to determine whether
deregulation of lncRNA expression (RNA-seq) alone can
predict patient survival outcomes. A secondary search for
significant predictors was performed in 1098 samples.
Compared to CNA, alterations of gene expression
were less frequent. For example, only 8 lncRNAs
were above 10% alteration frequency and 95 lncRNAs
revealed alternations in above 5% alternation frequency
(Table S2). Using Onco Query Language (OQL) EXP>2,
we found that 275 of 1098 cases had upregulation for
LINC00657, LINC00346, LINC00654 and HCG11;
total alteration frequency for these 4 lncRNAs was 26%
(Figure 2A). Unlike the first lncRNA signature primarily
due to CNA that all lncRNAs were clustered (Figure 1A),
these 4 lncRNAs were well separated (Figure 2B). For
example, they were either on different chromosomes or
they were at least 29 Mb apart if they are on the same

chromosome. Together, the association between lncRNA
upregulation and OS was highly significant (p = 1.432e5) (Figure 2C). In contrast to the first signature, CNA
of these 4 lncRNAs had no association with OS (Figure
S3). Individually, LINC00657 revealed 11% frequency of
alterations in 1098 samples and was the highest among
these four lncRNAs. Its upregulation was significantly
associated with OS (Figure S4A). The upregulation
frequency and p values for the other 3 lncRNAs
association with OS were shown in Figure S4B~D. Of
note, upregulation of these lncRNAs had no association
with recurrence (not shown).

A lncRNA signature for recurrence
Recurrence is a major concern for cancer survivors.
Since the first two signatures were not able to predict
recurrence, next we searched for a lncRNA signature

Figure 1: Identification of the first lncRNA signature associated with overall survival. A. Top 10 lncRNAs based on alteration
frequency primarily due to CNA and upregulation. B. Kaplan–Meier curve for OS due based on alterations of these 10 lncRNAs (CNA and
upregulation). C. Kaplan–Meier curve based on alterations of these 10 lncRNAs (CNA alone).
www.impactjournals.com/oncotarget
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for recurrence. There were 68 cases of recurrence in
this cohort (Table S4). We found that upregulation of
18 lncRNAs with p value <0.05 was associated with
recurrence (Table S5). To determine the optimal number
of lncRNAs for prediction of recurrence, we adopted
a stepwise forward selection approach based on Cox
model to identify lncRNAs significantly associated with
recurrence. 1) All variables were individually included in
the Cox model on recurrence. The variable with smallest
p value and below the 5% threshold was first selected. 2)
First, the remaining variables were evaluated in the Cox
model on recurrence with previously selected variable(s).
Next, the variable with smallest p value and below 5%

threshold entered the model. Finally, if any variable
became insignificant after inclusion of the new variable,
the insignificant variable was removed. We repeated
step 2 until none of the remaining variables having p
value less than 0.05. 3) All possible models based on the
selected variables are evaluated by AIC. The model with
the smallest AIC value was determined as the optimal
model.
Based on AIC estimation, 9 of 18 lncRNAs were
selected as a signature for prediction of recurrence (Figure
3A & 3B). Individually, they were upregulated with
alteration frequency of 2~5%, and together about 28% in
a total of 1105 samples (Figure 3A). Thus, this Cox based

Figure 2: LncRNA signature for OS based on RNA expression. A. Upregulation of LINC00657, LINC00346, LINC00654 and

HCG11 with alteration frequency. B. Organizations of these 4 lncRNAs and chromosome locations. C. Upregulation of these 4 lncRNAs is
significantly associated with OS as shown by Kaplan–Meier curve.
www.impactjournals.com/oncotarget
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search generated a third lncRNA signature consisting
of LINC00705, LINC00310, LINC00704, LINC00574,
FAM74A3, UMODL1-AS1, ARRDC1-AS1, HAR1A and
LINC00323 (Figure 3B). Upregulation of this signature
(exp > 2.0) was found in 228 of total 943 follow up cases;
it was distinctly different from the no upregulation group
(exp ≤ 2.0) with Gray’s test p < 0.001 (Figure 3C).

with overall survival in both HER-2 positive and HER-2
negative cases, the logrank test P-value was much smaller
for HER-positive than for HER-2 negative cases (Figure
4A & 4B). Furthermore, in HER-2 positive patients 5 year
survival rate was about 90% for cases with upregulation
of this signature compared to ~65%. In contrast, in HER-2
negative patients 5 year survival rate was ~85% for cases
with upregulation of this signature compared to ~65% for
cases without upregulation, implying poorer prognosis
for HER-2 positive patients with upregulation of this
signature than for HER-2 negative patients. For signature
3 we found that 5 year survival rate was about 90% for
cases with upregulation of this signature compared to
~80% for cases without upregulation (Figure 4C). In
contrast, in HER-2 negative patients 5 year survival rate
was ~90% for cases with upregulation of this signature
compared to ~65% for cases without upregulation (Figure
4D), suggesting poorer prognosis for HER-2 negative
patients with upregulation of this signature.
Next, we examined associations of alterations
for individual lncRNAs derived from signature 2 and
3 with ER, HER-2 or triple negative. Based on initial

Association of lncRNA signatures with
clinicopathologic features
Based on RNA expression we identified 2 signatures
(signature 2 and 3) consisting of 13 lncRNAs capable of
predicting OS or recurrence. Thus, we determined any
association of these lncRNAs with clinicopathologic
features including age, tumor stage, metastatic status,
ethnicity as well as the stature of ER, PR and HER-2.
Among them, we found no significant association with
age, tumor stage, metastatic status or ethnicity. However,
their expression was associated with HER-2. For
example, although expression of signature 2 (LINC00657,
LINC00346, LINC00654 and HCG11) was associated

Figure 3: LncRNA signature for recurrence based on RNA expression. A. Upregulation of 9 lncRNAs with alteration frequency.
B. Nine lncRNAs are selected as a signature for prediction of recurrence based on AIC estimation. C. Upregulation of these 9 lncRNAs is
significantly associated with recurrence.
www.impactjournals.com/oncotarget
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p values, 11 of 13 lncRNAs were associated with ER
status (Table S6). For example, in ER positive patients,
LINC00657 regulation accounted for 60%, but no
upregulation accounted for 71% In HER-2 positive
patients, 34% had upregulation of LINC00654 upregulation
accounted for 34%, no upregulation accounted for 66%. In
the triple negative group, alteration for each of 6 lncRNAs
(HCG11, LINC00310, LINC00704, UMODL1-AS1,
ARRDC1-AS1 and HAR1A) was significantly higher than
no alteration (Table S6).
Since the alteration frequency for each of these
lncRNA varies, along with 3 clinical conditions, to
integrate these variations, we applied the Bonferroni
correction to control the overall type I error rate at 5%. The
Bonferroni-adjusted P-value was calculated by multiplying

the raw P-value by 39. Table 1 shows the adjusted P-values
for associations between alterations of lncRNAs and
ER, HER-2 and triple negative status. After adjustment,
none of the lncRNAs was significantly associated with
HER-2 status. HCG11 and UMODL1-AS1 were both
significantly associated with ER and triple negative status.
Status of ER was also significantly associated with a few
other lncRNAs, including LINC00346, LINC00654,
LINC00704, and ARRDC1-AS1.

LINC00657 is a potential oncogenic gene
Upregulation of these lncRNAs is associated with
overall survival or recurrence, suggesting that they may
play an oncogenic role. Hence, we selected LINC00657

Figure 4: HER-2 status and OS or recurrence. A & B. A poorer OS with upregulation of signature 2 in HER-2 positive patients

than in HER-2 negative patients. C & D. A higher recurrence with upregulation of signature 3 in HER-2 negative patients than in HER-2
positive patients.
www.impactjournals.com/oncotarget
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Table 1: Alterations of lncRNAs associated with ER, PR and HER-2
ER

LINC00657

LINC00346

LINC00654

HCG11

LINC00705

LINC00310

LINC00704

LINC00574

FAM74A3

UMODL1AS1

HER-2

Positive N (%)

Bonferroniadjusted
P value

Alteration
(N=114)

68 (60%)

0.479

No alteration
(N=845)

603 (71%)

Alteration
(N=72)

14 (19%)

No alteration
(N=887)

657 (74%)

Alteration
(N=67)

23 (34%)

No alteration
(N=892)

648 (73%)

Alteration
(N=55)

14 (25%)

No alteration
(N=904)

657 (73%)

Alteration
(N=29)

14 (48%)

No alteration
(N=930)

657 (70%)

Alteration
(N=36)

18 (50%)

No alteration
(N=923)

653 (71%)

alteration
(N=19)

2 (11%)

No alteration
(N=940)

669 (71%)

Alteration
(N=36)

31 (86%)

No alteration
(N=923)

640 (69%)

Alteration
(N=36)

25 (69%)

No alteration
(N=923)

646 (70%)

Alteration
(N=42)

17 (40%)

No alteration
(N=917)

654 (71%)

Positive N Bonferroni- Positive N Bonferroni(%)
adjusted
(%)
adjusted
P value
P value
21 (18%)

1.000

164 (19%)
<0.0001

10 (14%)

23 (34%)

1.000

7 (13%)

0.129

4 (14%)

1.000

5 (14%)

1.000

7 (37%)

1.000

4 (11%)

1.000

4 (11%)

1.000

3 (11%)
182 (20%)

<0.0001

9 (31%)

1.000

15 (41%)

0.063

8 (42%)

0.653

3 (8%)

1.000

180 (20%)
1.000

181 (20%)
0.002

33 (60%)

175 (19%)

181 (20%)
1.000

1.000

168 (19%)

178 (19%)
1.000

13 (19%)

174 (19%)

180 (20%)
<0.0001

1.000

150 (16%)

181 (19%)
0.565

16 (22%)

170 (19%)

178 (20%)
0.514

1.000

167 (19%)

165 (18%)
<0.0001

20 (18%)
163 (27%)

175 (20%)
<0.0001

Triple negative

6 (17%)

1.000

177 (19%)
1.000

18 (43%)

0.014

165 (18%)
(Continued )
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ER

ARRDC1AS1

LINC00323

HAR1A

HER-2

Positive N (%)

Bonferroniadjusted
P value

Alteration
(N=31)

12 (39%)

<0.0001

No alteration
(N=928)

659 (71%)

Alteration
(N=37)

24 (65%)

No alteration
(N=922)

647 (70%)

Alteration
(N=26)

24 (92%)

No alteration
(N=933)

647 (69%)

4 (13%)

1.000

4 (11%)

0.346

3 (12%)
182 (19%)

13 (42%)

1.000

170 (18%)
1.000

181 (20%)

to determine its effect on breast cancer because alteration
of LINC00657 with RNA expression occurred at 11%
frequency, the highest among the 4 lncRNA signature
(Figure 2A). Moreover, LINC00657 has been recently
shown to play a role in genomic stability [17]. To this end,
we first profiled breast cancer cDNA arrays from OriGene
consisting of 43 tumor and 5 normal. In 9 of 43 samples
(21%) LINC00657 expression level was above a 2-fold
of the mean expression level (Figure 5A). Consistent
with this finding, we found that LINC00657 was also
upregulated in breast cancer cell lines MCF-7 and MDAMB-231 cells as compared to non-malignant HMLE cells
(Figure 5B).
Therefore, we knocked out LINC00657 by CRISPR/
Cas9 system (Figure S5) in LM-4142, a derivative cell line
from MDA-MB-231 [18]. We selected two of them for
further characterization (Figure 5C, RT-PCR data). MTT
assays indicated that LINC00657 KO caused significant
reduction of cell growth (Figure 5D). Consistent with
this result, clonogenic assays indicated that the number
of colonies was much smaller in KO cells than in vector
control (Figure 5E). These results suggest that LINC0657
impacts tumor cell proliferation and cell growth and thus,
LINC00657 is a potential oncogene gene.

10 (27%)

1.000

173 (19%)
1.000

1 (3%)

1.000

182 (19%)

three specific lncRNA signatures: 1) lncRNA signature
based on alterations of CNA and RNA expression that
is associated with OS; 2) lncRNA signature based on
alterations of RNA expression alone that is associated
with OS; and 3) lncRNAs based on alternations of RNA
expression alone that is associated with recurrence.
Together, our study suggests that lncRNAs are potential
prognostic markers for breast cancer and thus further
investigations of these lncRNAs are warranted.
Early work of biomarker discovery in breast cancer
focuses on protein-coding genes such as Ki-67, ER, PR,
and HER-2 [19]. For example, expression of ERα is a
well-established prognostic factor in breast cancer patients
[20]. Other molecular biomarkers include p53, p14ARF,
cyclin D1, cyclin E, TBX2/3, and VEGF [21] and genetic
mutations such as BRCA1 and BRCA2 [22]. Furthermore,
several multigene signature have been developed in recent
years to predict risk of breast cancer recurrence after a
primary diagnosis [23, 24]. In particular, Oncotype-Dx,
(Genomic Health) consisting of 21 genes, can provide
treatment recommendations in conjunction with risk
of recurrence [25]. Compared to protein-coding genes,
the number of lncRNAs is much larger [26], and thus,
lncRNAs should be a rich source for biomarker discovery.
Therefore, potential lncRNA signatures would at least
complement the existing biomarkers, providing additional
information that may help improve the predictability.
Interrogation of this dataset provides a new
perspective on the role of lncRNAs as biomarkers for
breast cancer diagnosis prognosis. Although early studies
have shown that lncRNAs may serve as prognostic
markers, their functional role in prognosis may vary
even with the same lncRNA. HOTAIR is one of the early
identified lncRNAs and plays a significant role in gene
regulation through remodeling chromatin structures [27].

DISCUSSION
Despite large numbers of human lncRNAs identified
so far, little is known whether they can serve as markers
for cancer diagnosis/prognosis. The present study focus
on a special group of lncRNAs from HGNC to interrogate
the breast invasive carcinoma dataset (provisional) at the
cBioPortal. This dataset consists of 960 complete tumor
samples and over 1000 samples with RNA expression
(RNA-seq) data. From over 2700 lncRNAs we identify
www.impactjournals.com/oncotarget

Positive N Bonferroni- Positive N Bonferroni(%)
adjusted
(%)
adjusted
P value
P value

184 (20%)
1.000

Triple negative
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Importantly, elevated expression of HOTAIR was reported
in both primary and metastatic breast cancer and it is a
significant predictor of subsequent metastasis and death
[28]. Moreover, Sorensen et al showed that HOTAIR is
a prognostic marker of metastasis in ER positive breast
cancer from 164 patients by microarray analysis [29].
However, Gokmen-Polar et al [30] reported that HOTAIR
was only a poor prognostic indicator in ER negative breast
cancer from 952 patients in TCGA database. In contrast,
high HOTAIR expression had lower risks of relapse and
mortality than those with low HOTAIR expression through
336 breast cancer patients [31]. Several possibilities
may contribute to the conflicting results. First, detection

methods are different in these studies, including qRT-PCR,
microarray analysis and HOX tiling array. Second, the cutoff value of high and low HOTAIR expression as well as
ER status in these studies may be different. Third, there
is a significant heterogeneity in these studies, such as
the races, the tumor sizes and the clinical stages. These
factors may also explain why HOTAIR does not meet the
cut as a prognostic marker in our study. Alternatively, the
signatures identified in this study may be more potentially
as diagnostic markers than HOTAIR.
Although the role of these lncRNAs within three
signatures in breast cancer remains to be determined yet,
their association with cancer death or recurrence may

Figure 5: Upregulation of LINC00657 in breast cancer and its promotion of cell growth and proliferation. A. Expression

of LINC00657 in the OriGene breast cancer tissue cDNA array, as determined by qPCR. B. LINC00657 is upregulated in breast cancer cells
(MCF-7 and MDA-MB-231) as compared to non-malignant breast cells (HMLE). C. Expression of LINC00657 in KO cells as compared to
vector control. D & E. LINC00657 KO suppresses cell growth, as detected by MTT assays and colony formation, as detected by clonogenic
assays. Values in B, C, D, E and F are SEM (n = 3). *, p < 0.05; **, p < 0.01.
www.impactjournals.com/oncotarget
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suggest that they play an oncogenic role. Since the first
signature consists of lncRNAs primarily due to CNA,
they are clustered in close association with Myc. Thus,
the possible oncogenic role, if any, is likely from Myc. In
particular, not all amplification cases cause upregulation
of their corresponding lncRNAs. On the other hand, both
the second and third signatures consist of lncRNAs solely
due to upregulation and they are well separated, and the
upregulation of these lncRNAs may suggest that they may
function as drivers. In support of this notion, we showed
that LINC00657 may play an oncogenic role. For example,
LINC00657 KO suppresses cell growth and proliferation.
Thus, LINC00657 may serve as not only a biomarker, but
also a potential therapeutic target.
Given the clinical potential of these lncRNAs
identified in this this study, it would be interesting to
determine whether they can also be detected in the
circulation system. In support of this possibility, recent
studies suggest that serum lncRNAs may serve as potential
biomarkers for hepatocellular carcinoma and breast cancer
[32–34]. In addition, lncRNAs can also be present in
urine. For example, prostate cancer antigen 3 (PCA3 or
DD3) is a lncRNA that is highly overexpressed in prostate
cancer. In particular, presence of PCA3 in urine can
predict prostate biopsy outcome [35]. Therefore, further
characterization of them is warranted.
Finally, in addition to biomarker discovery, this
study provides an example of how researchers with little
knowledge in bioinformatics can utilize the existing public
data for lncRNA research. Given the overwhelming number
of lncRNAs, a challenge for average research laboratories
is how to focus on lncRNAs with clinical relevance. The
cBioPortal might be a good start point before launching
real experiments. The portal currently contains data from
105 cancer genomics studies and a variety of cancer types.
Since the dataset we used in this study is still provisional, the
number of samples keep increasing. We expect that this may
further enhance the predictability in future.

Genomic data types integrated by cBioPortal included
somatic mutations, DNA copy number alterations (CNAs),
mRNA and microRNA expression, DNA methylation,
protein abundance, and phosphoprotein abundance.
The portal contained several sets of samples for breast
cancer. From Breast Invasive Carcinoma dataset (TCGA,
provisional) as shown in Figure S6, we chose 1) “All
complete tumors with 960 samples (when the primary
search was performed) or 2) tumors with mRNA data (RNAseq V2) from 1098 or 1105 samples. The primary search
parameters included mutations, CNA from GISTIC and
mRNA expression (RNA seq data) with the default setting.
For the secondary search, we focused on RNA seq data.

Statistical analysis
All available lncRNAs were sorted by alteration
frequency at the cBioPortal. Those lncRNAs with
significant log-rank p values were entered the candidate
pool to be considered for further selection. The forward
selection was performed among the pool of candidates
by using the Cox model on progression. The Akaike
information criterion (AIC) was further evaluated for
the models that were finalized at each step of forward
selection. The model with smallest AIC value was chosen
as the final model and the lncRNAs in the final model
were identified as predictors of progression. The study
cohort of breast cancer patients were divided into those
with high expression on any of the predictors and those
with normal expressions on these predictors. Progression
and death without progression were treated as competing
risks. The cumulative incidence of progression was
estimated in the aforementioned two patient subgroups.
The difference in cumulative incidence of progression
between two subgroups was evaluated by the Gray’s test
[38]. P values less than 5% were determined as significant.
The statistical analyses were performed using the SAS
software (version 9.3, the SAS institute) and R package
“cmprsk” for competing risks analysis.

MATERIALS AND METHODS

Cell culture

Database search

LM-4142 cells originally derived from MDAMB-231 were kindly provided by Dr. Joan Massagué
(Memorial Sloan-Kettering Cancer Center) as described
previously [18]. Cells were cultured in RPMI-1640
medium with 10% FBS and 2mM glutamine. All culture
media were supplemented with 100 units/mL penicillin
and 100 μg/mL streptomycin.

The cBioPortal (http://www.cbioportal.org) is
an open-access resource for interactive exploration of
multidimensional cancer genomics data sets, currently
providing access to data from more than 5,000 tumor
samples from 105 cancer studies in the TCGA pipeline [36,
37]. Although there are overwhelming numbers of human
lncRNAs reported from databases, the nomenclature of
lncRNAs is still incomplete. In this study we focused
on those lncRNAs by HUGO gene nomenclature
committee (HGNC) (http://www.genenames.org/) where
we downloaded a total of 2730 lncRNAs (http://www
.genenames.org/cgi-bin/statistics) (Table S1) for our
analysis when this study was initiated.
www.impactjournals.com/oncotarget

qRT-PCR
Total RNA was isolated using Direct-zol™ RNA
MiniPrep Kit (Zymo Research, Irvine, CA) as suggested
by manufacturer. Reverse transcription was carried out by
using RevertAid Reverse Transcriptase (Fisher Scientific)
and random primer mix (New England BioLabs, Ipswich,
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MA). The expression of lncRNAs was detected by
quantitative RT-PCR (qRT-PCR) using SYBR Green
method. Analysis of qRT-PCR was performed as described
previously [39].

days after seeding, colonies were fixed and stained with
0.1% crystal violet.

Construction of plasmids
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